Skip to Content
Translational Research Program (TRP)
Contact CIP
Show menu
Search this site
Last Updated: 10/10/18

Hepatobiliary Cancer SPORE

In 2018 an estimated 42,220 adults in the U.S. will be diagnosed with hepatobiliary cancer leading to 30,200 deaths. This includes hepatocellular carcinoma (HCC), which is the most common form of liver cancer, and a form of bile duct cancer called cholangiocarcinoma. The mortality rates of this cancer are rising faster than any other cancer: on average 2.6% per year. Hepatobiliary cancer is even more common in other parts of the world such as sub-Saharan Africa and southeast Asia. So far, only one drug has gained FDA-approval for liver cancer: the kinase inhibitor sorafenib approved in 2007 for treatment of unresectable HCC. However, sorafenib only extends time to progression by a few months and there is a dire need for more effective therapies. SPORE funding was awarded in 2018 to the Mayo Clinic (and collaborators at other institutions) to carry out four projects focusing on novel approaches to hepatobiliary cancer diagnosis and therapy.